GLS and SLC1A5 inhibitors have shown efficacy in preclinical models and are under trials; Glutamine can act as an intercellular metabolic checkpoint and modulate tumor immunity; and ASNS could be a vulnerability in gastric and liver cancer tumor cells, suggesting l-asparaginase as a potential therapy50–52. This evidence concerns the gene SLC1A5 and liver cancer.